Cardiac Autonomic Modulation in Older Hypertensive Individuals Submitted to Different Types of Physical Training

November 19, 2021 updated by: Nereida Kilza da Costa Lima, University of Sao Paulo
Sixty-one sedentary older hypertensive individuals were randomized to four groups: continuous aerobic training (CA), interval aerobic training (IA), resistance training (R), and control (C) group. The protocol included 3 sessions of training by week for 12 weeks. C individuals were instructed to continue their usual activities. They were submitted to the passive tilt test before and after the research protocol, evaluating the heart rate (HR), low frequency (LF) and high frequency (HF) bands, detrended fluctuation analysis (DFAα1) and entropy

Study Overview

Status

Completed

Intervention / Treatment

Detailed Description

The individuals were randomized into four groups: continuous aerobic training (CA), interval aerobic training (IA), resistance training (R), and control (C), which performed physical exercises three times a week for twelve weeks, with a total of 36 sessions. The tilt test was performed before and after the research protocol. Individuals in the control group were only encouraged to maintain their usual activities.

For the analysis of HRV, the baseline conditions (resting in the supine position) were determined, followed by the passive postural maneuver, which characterizes the tilt test (table til tat 70 °) in order to determine the following variables:

  • HR: heart rate (sympathetic action)
  • LF: Low frequency band (Modulated predominantly by the sympathetic system)
  • HF: High frequency band (Modulated predominantly by the parasympathetic system)
  • Entropy: data complexity or irregularity index showing that, the higher the values, the better the HRV.
  • DFAα1 (short term detrended fluctuation analysis)

Study Type

Interventional

Enrollment (Actual)

61

Phase

  • Not Applicable

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

60 years and older (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Inclusion Criteria:men and women 60-year-old or older, extensively using prescription antihypertensive drugs, and having no previous experience with physical training -

Exclusion Criteria:

  • • Positive treadmill test (TT) for ischemia

    • Related left ventricular systolic dysfunction of any degree
    • Presence of arrhythmias
    • Use of β-blockers
    • Use more than seven doses of ethyl alcohol per week
    • Renal insufficiency
    • Diabetes
    • Hyper- or hypothyroidism
    • Limiting lung disease
    • Osteomioarticular impairment that would limit exercise performance
    • SBP ≥160 and/or DBP ≥ 100 mmHg on baseline

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: TREATMENT
  • Allocation: RANDOMIZED
  • Interventional Model: PARALLEL
  • Masking: NONE

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
EXPERIMENTAL: continuous aerobic training (CA)
The CA group was trained with 70% of maximum heart rate (MHR) for 30 minutes.
3 different types of training or control
EXPERIMENTAL: resistance training (R)
The R sessions consisted of a set of each proposed exercise: sitting bench press, legpress, back row, leg extension, shoulders high pull, seated leg curl, biceps curls, standing calf, triceps in the pulley, and abdominal crunches, with 8 - 10 repetitions with 75% 1MR.
3 different types of training or control
EXPERIMENTAL: interval aerobic training (IA)
The IA group was submitted to exercise intensities of 60% for 2 minutes and 80% for 2 minutes, alternately, with a total of 30 minutes.
3 different types of training or control
NO_INTERVENTION: control (C)
Individuals in the control group maintained their usual activities.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Heart rate
Time Frame: 12 weeks
Heart rate was obtained before and after the protocol by electrocardiogram, performed before and after tilt test at each time.
12 weeks
Low frequency band
Time Frame: 12 weeks
Low frequency band was obtained before and after the protocol by electrocardiogram, performed before and after tilt test at each time.The electrical signal from the electrocardiogram was filtered and amplified. The amplified signals were processed by ananalog-digital converter (DI-720, DATAQ Instruments, Akron, OH, USA) and sampled (1000 hz per channel) by a computer program (Windaq, DATAQ, Akron, OH, USA) installed in an IBM/PC computer.
12 weeks
High frequency band
Time Frame: 12 weeks
High frequency band was obtained before and after the protocol by electrocardiogram, performed before and after tilt test at each time.The electrical signal from the electrocardiogram was filtered and amplified. The amplified signals were processed by ananalog-digital converter (DI-720, DATAQ Instruments, Akron, OH, USA) and sampled (1000 hz per channel) by a computer program (Windaq, DATAQ, Akron, OH, USA) installed in an IBM/PC computer.
12 weeks
Entropy
Time Frame: 12 weeks
Entropy was obtained before and after the protocol by electrocardiogram, performed before and after tilt test at each time.The electrical signal from the electrocardiogram was filtered and amplified. The amplified signals were processed by ananalog-digital converter (DI-720, DATAQ Instruments, Akron, OH, USA) and sampled (1000 hz per channel) by a computer program (Windaq, DATAQ, Akron, OH, USA) installed in an IBM/PC computer.
12 weeks
Short term detrended fluctuation analysis
Time Frame: 12 weeks
Short term detrended fluctuation analysis obtained before and after the protocol by electrocardiogram, performed before and after tilt test at each time.The electrical signal from the electrocardiogram was filtered and amplified. The amplified signals were processed by ananalog-digital converter (DI-720, DATAQ Instruments, Akron, OH, USA) and sampled (1000 hz per channel) by a computer program (Windaq, DATAQ, Akron, OH, USA) installed in an IBM/PC computer.
12 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ACTUAL)

January 10, 2015

Primary Completion (ACTUAL)

June 10, 2017

Study Completion (ACTUAL)

July 10, 2017

Study Registration Dates

First Submitted

November 9, 2021

First Submitted That Met QC Criteria

November 19, 2021

First Posted (ACTUAL)

November 26, 2021

Study Record Updates

Last Update Posted (ACTUAL)

November 26, 2021

Last Update Submitted That Met QC Criteria

November 19, 2021

Last Verified

November 1, 2021

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

Individual data of volunteers, without identification, can be provided if requested by other authors, through contact with the main researcher

IPD Sharing Time Frame

Data will be made available after the publication of the study, with no time to end sharing

IPD Sharing Access Criteria

contact with the main researcher

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Autonomic Dysfunction

Clinical Trials on Exercise

3
Subscribe